These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18006057)

  • 21. [The myelodysplastic syndrome and autoimmunity].
    Laursen SB; Nielsen MØ; Hasselbalch HC
    Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
    Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
    Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS).
    Economopoulou C; Pappa V; Kontsioti F; Papageorgiou S; Kapsimali V; Papasteriadi C; Economopoulou P; Papageorgiou E; Dervenoulas J; Economopoulos T
    Leuk Res; 2008 Jan; 32(1):61-9. PubMed ID: 17597205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
    Bacher U; Haferlach T; Kern W; Weiss T; Schnittger S; Haferlach C
    Cancer; 2009 Oct; 115(19):4524-32. PubMed ID: 19569249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell activation in patients with irritable bowel syndrome.
    Ohman L; Isaksson S; Lindmark AC; Posserud I; Stotzer PO; Strid H; Sjövall H; Simrén M
    Am J Gastroenterol; 2009 May; 104(5):1205-12. PubMed ID: 19367268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
    Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
    Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
    Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
    Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.
    Maftoun-Banankhah S; Maleki A; Karandikar NJ; Arbini AA; Fuda FS; Wang HY; Chen W
    Am J Clin Pathol; 2008 Feb; 129(2):300-8. PubMed ID: 18208811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
    Slovak ML; O'Donnell M; Smith DD; Gaal K
    Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients.
    Dalamaga M; Karmaniolas K; Matekovits A; Migdalis I; Papadavid E
    J Eur Acad Dermatol Venereol; 2008 May; 22(5):543-8. PubMed ID: 18070024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?
    Fozza C; Longinotti M
    Eur J Haematol; 2012 May; 88(5):380-7. PubMed ID: 22296182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated cellular senescence in myelodysplastic syndrome.
    Wang YY; Cen JN; He J; Shen HJ; Liu DD; Yao L; Qi XF; Chen ZX
    Exp Hematol; 2009 Nov; 37(11):1310-7. PubMed ID: 19748549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.
    Sand K; Theorell J; Bruserud Ø; Bryceson YT; Kittang AO
    Cancer Immunol Immunother; 2016 Sep; 65(9):1135-47. PubMed ID: 27481108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The frequency, activation, and coreceptor expression of lymphocytes in human immunodeficiency virus/hepatitis C virus co-infected patients in China.
    Shi W; Zhang Z; Zhang M; Liu J; Jiang Y; Wang Y; Jin X; Han X; Shang H
    Jpn J Infect Dis; 2009 Jul; 62(4):284-8. PubMed ID: 19628906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chromosomal structural changes in patients with myelodysplastic syndrome].
    Yu Y; Liu XP; Liu SH; Yu MH; Zhang Y; Xiao ZJ
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2693-7. PubMed ID: 18167247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Karyotypic analysis of bone marrow cells in pyodermic lesions associated with myelodysplastic syndrome.
    Hamada T; Matsuura H; Oono T; Morizane S; Yamasaki O; Asagoe K; Yamamoto T; Tsuji K; Iwatsuki K
    Arch Dermatol; 2008 May; 144(5):643-8. PubMed ID: 18490591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human C-reactive protein activates monocyte-derived dendritic cells and induces dendritic cell-mediated T-cell activation.
    Van Vré EA; Bult H; Hoymans VY; Van Tendeloo VF; Vrints CJ; Bosmans JM
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):511-8. PubMed ID: 18218989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.